Expression of phosphorylated histone H2AX (γ-H2AX) in normal and neoplastic squamous epithelia of the uterine cervix: An immunohistochemical study with epidermal growth factor receptor

International Journal of Gynecological Pathology

Volumn 30, Issue 1, 2011, Pages 76-83

  Brustmann, Hermann ^a   Hinterholzer, Susanne ^a   Brunner, Andreas ^a  

^a Landesklinikum Thermenregion ^*  (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE GAMMA H2AX; HISTONE H2AX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; PHOSPHOPROTEINS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; UTERINE CERVICAL NEOPLASMS;

EID: 78650943328     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181eb2fcb     Document Type: Article

References (26)

1. Thiriet C, Hayes JJ. Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to repair. Molecular Cell 2005;18:617-22.
2. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21-6.
3. Alvarez G, Perry A, Tan BR, et al. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol 2006; 19:942-49.
4. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985;313:745-47.
5. Calvo E, Rowinsky EK. Clinical experience with monoclonal antibodies to epidermal growth factor receptor. Curr Oncol Rep 2005;7:96-103. (Pubitemid 40485464)
6. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
7. Clifford G, Franceschi S, Diaz M, et al. HPV type-distribution in women with and without cervical neoplastic disease. Vaccine 2006;24S3:S3/26-S3/34.
8. Chapman WB, Lorincz AT, Willett GD, et al. Epidermal growth factor receptor expression and the presence of human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynecol Pathol 1992;11:221-6.
9. Shen L, Shui Y, Wang X, et al. EGFR and Her2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. BMC Cancer 2008; 8:232.
10. Nucci MR, Oliva E. Gynecologic Pathology. In: Goldblum JR, ed. Foundations in Diagnostic Pathology. Elsevier Churchill Livingstone; 2009.
11. Baltazar F, Filho AL, Pinheiro C, et al. Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. Int J Gynecol Pathol 2007;26:235-41.
12. Wasco MJ, Pu RT, Yu L, et al. Expression of c-H2AX in melanocytic lesions. Hum Pathol 2008;39:1614-20.
13. Bartkova J, Horejsi Z, Koek K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
14. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;435:907-13. (Pubitemid 40559004)
15. Fragkos M, Jurvansuu J, Beard P. H2AX is required for cell cycle arrest via the p53/p21 pathway. Mol Cell Biol 2009; 29:2828-40.
16. Kruse AJ, Skaland I, Janssen EA, et al. Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability. Int J Gynecol Pathol 2004;23:100-9.
17. Kuo LJ, Yang LX. Gamma-H2AX-a novel biomarker for DNA double-strand breaks. In Vivo 2008;22:305-9.
18. Bonner WM, Redon CE, Dickey JS, et al. GammaH2AX and cancer. Nat Rev Cancer 2008;8:957-67.
19. Park I, Park KK, Park JH, et al. Isoliquiritigenin induces G2 and M phase arrest by inducing DNA damage and by inhibiting the metaphase/anaphase transition. Cancer Lett 2009;277:174-81.
20. Munshi A, Kurland JF, Nishikawa T, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005;11: 4912-22.
21. Yang YC, Chao KS, Lin CP, et al. Oxaliplatin regulates DNA repair responding to ionizing radiation and enhances radiosensitivity of human cervical cancer cells. Int J Gynecol Cancer 2009;19:782-86.
22. Boiko IV, Mitchell MF, Hu W, et al. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an a-difluoromethylornithine chemprevention trial. Clin Cancer Res 1998;4:1383-91.
23. Kim JW, Kim YT, Kim DK, et al. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol Oncol 1996;60:283-87.
24. Bellone S, Frera G, Landolfi G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 2007;106: 513-20.
25. Brustmann H. Epidermal growth factor receptor is involved in the development of an invasive phenotype in vulvar squamous lesions, but is not related to MIB-1 immunoreactivity. Int J Gynecol Pathol 2007;26:481-9.
26. Mathur SP, Mathur RS, Rust PF, et al. Human papilloma virus (HPV)-E6/E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN). Am J Reprod Immunol 2001; 46:280-7.